Plain-English translation of NCT06148402 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether fruquintinib, camrelizumab, and capecitabine—three medications used together—can help treat advanced colorectal cancer in people whose cancer has stopped responding to standard first-line chemotherapy. The study will enroll 30 patients and measure how well the medication shrinks tumors and improves survival. Researchers hope this combination could become a new option for patients who need additional treatment after their initial therapy.
While doctors know that certain chemotherapy combinations work well as a first treatment for advanced colorectal cancer, there is no standard treatment recommendation for patients whose cancer gets worse after that initial therapy. This trial explores whether the medication could fill that gap and offer hope to patients who need second-line treatment options.
You will take the medication as an outpatient, receiving fruquintinib as a daily pill (2 weeks on, 1 week off), camrelizumab as an injection every 3 weeks, and capecitabine as pills twice daily (2 weeks on, 1 week off, repeated every 3 weeks). You will visit the clinic regularly for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and to watch for side effects. The study will track how your cancer responds, how long you survive, and whether a blood test called ctDNA can predict how well you respond to treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China